
浏览全部资源
扫码关注微信
1.075000 河北 张家口,河北北方学院研究生学院
2.518112 广东 深圳,深圳市第三人民医院放射科
3.518112 广东 深圳,深圳市第三人民医院超声科
[李志艳,E-mail:lzyyuer@sina.com LI Zhiyan, E-mail: lzyyuer@sina.com
收稿:2022-08-12,
修回:2022-09-30,
纸质出版:2023-03-15
移动端阅览
刘亚莉, 许国宇, 李志艳, 等. 超声造影肝脏影像报告-数据系统与欧洲超声造影指南对肝脏结节良恶性鉴别的诊断效能对比[J]. 陆军军医大学学报, 2023,45(5):462-467.
Yali LIU, Guoyu XU, Zhiyan LI, et al. Diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system versus European CEUS guidelines for liver malignant tumors[J]. Journal of Army Medical University, 2023, 45(5): 462-467.
刘亚莉, 许国宇, 李志艳, 等. 超声造影肝脏影像报告-数据系统与欧洲超声造影指南对肝脏结节良恶性鉴别的诊断效能对比[J]. 陆军军医大学学报, 2023,45(5):462-467. DOI: 10.16016/j.2097-0927.202208077.
Yali LIU, Guoyu XU, Zhiyan LI, et al. Diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system versus European CEUS guidelines for liver malignant tumors[J]. Journal of Army Medical University, 2023, 45(5): 462-467. DOI: 10.16016/j.2097-0927.202208077.
目的
2
对比超声造影肝脏影像报告-数据系统(contrast-enhanced ultrasound liver imaging reporting and data system,CEUS LI-RADS)与欧洲超声造影指南对肝细胞癌(hepatocellular carcinoma,HCC)高危人群肿瘤良恶性鉴别的诊断效能。
方法
2
筛选2020年8月至2022年1月在深圳市第三人民医院就诊的89例疑似HCC病例的影像学资料,其中男性74例,女性15例,年龄22~77(50.8±11.3)岁。以病理诊断为金标准,采用受试者工作曲线(receiver operating characteristic curve,ROC)分析并计算CEUS LI-RADS和欧洲CEUS指南的ROC曲线下面积(area under the subject curve,AUC)值。计算CEUS LR-5+LR-M与欧洲CEUS指南诊断肝脏恶性肿瘤的敏感性、特异性、阳性预测值、阴性预测值及准确性。
结果
2
92个病灶中77个病灶经CEUS归类为LR-5+LR-M,77个病灶经欧洲CEUS指南诊断为恶性肿瘤,75个病灶经病理证实为肝脏恶性肿瘤。CEUS LI-RADS和欧洲CEUS指南的AUC值分别为0.875、0.797,差异无统计学意义(
Z
=1.71
P
=0.088)。以LR-5、LR-M类病灶为阳性结果,CEUS LR-5+LR-M与欧洲CEUS指南诊断肝脏恶性肿瘤的敏感性为97.3%(95%
CI
: 90.7%~99.7%)、94.7%(95%
CI
: 86.9%~98.5%)(χ
2
=8.12,
P
=0.004),特异性为76.5%(95%
CI
: 50.1%~93.2%)、64.7%(95%
CI
: 38.3%~85.8%),阳性预测值为94.8%、92.2%,阴性预测值为86.7%、73.3%,准确性为93.5%(95%
CI
: 86.3%~97.6%)、89.1%(95%
CI
: 80.9%~94.7%)(χ
2
=20.63,
P
<0.001)。
结论
2
CEUS LI-RADS与欧洲CEUS指南对HCC高危人群肿瘤良恶性鉴别的诊断效能相当,CEUS LI-RADS的敏感性和准确性更高。
Objective
2
To investigate the diagnostic value of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) and European CEUS guidelines for liver malignant tumors in high-risk patients with hepatocellular carcinoma (HCC).
Methods
2
The imaging data of 89 high-risk patients with suspected HCC treated in Shenzhen Third People's Hospital from August 2020 to January 2022 were retrospectively analyzed. They were 74 males and 15 females
and aged between 22 and 77 (50.8±11.3) years. Pathological diagnosis was used as the gold standard
and receiver operating characteristic (ROC) curve analysis was adopted to calculate the areas under the ROC curve (AUC) of CEUS LI-RADS and European CEUS guidlines. And the sensitivity
specificity
positive predictive value (PPV)
negative predictive value (NPV) and accuracy of CEUS LR-5+LR-M and European CEUS guidelines for diagnosing liver malignancies were calculated.
Results
2
Of the 92 lesions
77 lesions were classified as LR-5+LR-M by CEUS
and 77 lesions were diagnosed liver malignant tumors by European CEUS guidelines
and 75 lesions were pathologically confirmed to be malignant tumors of the liver. The AUC values of CEUS LI-RADS and European CEUS guidelines were 0.875 and 0.797
respectively
through no statistical difference (
Z
=1.71
P
=0.088). Taking LR-5 and LR-M lesions as positive results
the sensitivity
specificity and PPV
NPV and accuracy were 97.3% (95%
CI
: 90.7%~99.7%) and 94.7% (95%
CI
: 86.9%~98.5%
Chi
-square=8.12
P
=0.004)
76.5% (95%
CI
: 50.1%~93.2%) and 64.7% (95%
CI
: 38.3%~85.8%)
94.8% and 92.2%
86.7% and 73.3%
and 93.5% (95%
CI
: 86.3%~97.6%) and 89.1% (95%
CI
: 80.9%~94.7%
Chi
-square=20.63
P
<
0.001) in CEUS LR-5+LR-M and European CEUS guidelines for diagnosing liver malignancies
respectively.
Conclusion
2
CEUS LI-RADS shows comparable diagnostic performance as European CEUS guidelines
but the sensitivity and accuracy of CEUS LI-RADS are significantly higher.
CRAIG A J, VON FELDEN J, GARCIA-LEZANA T, et al . Tumour evolution in hepatocellular carcinoma[J ] . Nat Rev Gastroenterol Hepatol, 2020, 17(3): 139-152. DOI: 10.1038/s41575-019-0229-4.
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(2): 143-168. DOI: 10.3760/cma.j.cn115610-20220124-00053.
Bureau of Medical Administration of National Health Commission of the People's Republic of China. Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)[J]. Chin J Dig Surg, 2022, 21(2): 143-168. DOI: 10.3760/cma.j.cn115610-20220124-00053.
CHEN T J, CHANG X Y, LV K, et al . Contrast-enhanced ultrasound features of intrahepatic cholangiocarcinoma: a new perspective[J ] . Sci Rep, 2019, 9(1): 19363. DOI: 10.1038/s41598-019-55857-6.
WILSON S R, LYSHCHIK A, PISCAGLIA F, et al . CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI[J ] . Abdom Radiol (NY), 2018, 43(1): 127-142. DOI: 10.1007/s00261-017-1250-0.
DIETRICH C F, NOLSØE C P, BARR R G, et al . Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS[J ] . Ultrasound Med Biol, 2020, 46(10): 2579-2604. DOI: 10.1016/j.ultrasmedbio.2020.04.030.
American College of Radiology. CEUS LI-RADS v2017 Core[EB/OL]. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CEUS-LI-RADS-v2017.2019.07.19.
ZUO D S, YANG K F, WU S Z. Diagnostic performance of intravascular perfusion based contrast-enhanced ultrasound LI-RADS in the evaluation of hepatocellular carcinoma[J]. Clin Hemorheol Microcirc, 2021, 78(4): 429-437. DOI: 10.3233/CH-211164.
MAKOYEVA A, KIM T K, JANG H J, et al . Use of CEUS LI-RADS for the accurate diagnosis of nodules in patients at risk for hepatocellular carcinoma: a validation study[J ] . Radiol Imaging Cancer, 2020, 2(2): e190014. DOI: 10.1148/rycan.2020190014.
LI S, ZHOU L, CHEN R, et al . Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data S ystem (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma[J ] . Clin Radiol, 2021, 76(2): 161.e1-161.e10. DOI: 10.1016/j.crad.2020.10.009.
SHIN J, LEE S, BAE H, et al . Contrast-enhanced ultrasound liver imaging reporting and data system for diagnosing hepatocellular carcinoma: a meta-analysis[J ] . Liver Int, 2020, 40(10): 2345-2352. DOI: 10.1111/liv.14617.
FERRAIOLI G, MELONI M F. Contrast-enhanced ultrasonography of the liver using SonoVue[J]. Ultrasonography, 2018, 37(1): 25-35. DOI: 10.14366/usg.17037.
GUO Y Y, QIN X C, CHEN S X, et al . Diagnosis efficacy of CEUS for hepatic inflammatory lesions[J ] . J Clin Lab Anal, 2020, 34(6): e23231. DOI: 10.1002/jcla.23231.
马霞, 胡向东, 谭小蕖, 等. 肝脏局灶性炎性病变的常规超声及超声造影表现[J]. 中国医学装备, 2019, 16(10): 74-77. DOI: 10.3969/J.ISSN.1672-8270.2019.10.021.
MA X, HU X D, TAN X Q, et al . Manifestations of conventional ultrasound and contrast-enhanced ultrasound imaging of focal inflammatory lesion of liver[J ] . China Med Equip, 2019, 16(10): 74-77. DOI: 10.3969/J.ISSN.1672-8270.2019.10.021.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621